TW200745034A - New compounds - Google Patents

New compounds

Info

Publication number
TW200745034A
TW200745034A TW095132103A TW95132103A TW200745034A TW 200745034 A TW200745034 A TW 200745034A TW 095132103 A TW095132103 A TW 095132103A TW 95132103 A TW95132103 A TW 95132103A TW 200745034 A TW200745034 A TW 200745034A
Authority
TW
Taiwan
Prior art keywords
hydrogen
new compounds
formula
medicament
substituted
Prior art date
Application number
TW095132103A
Other languages
English (en)
Chinese (zh)
Inventor
Hitoshi Yamazaki
Chiyoshi Kasahara
Hirokazu Kubota
Toru Kontani
Toru Asano
Hidekazu Mizuhara
Masaharu Yokomoto
Keiji Misumi
Tomohiko Kinoshita
Original Assignee
Astellas Pharma Inc
Wakunaga Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc, Wakunaga Pharma Co Ltd filed Critical Astellas Pharma Inc
Publication of TW200745034A publication Critical patent/TW200745034A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW095132103A 2005-09-01 2006-08-31 New compounds TW200745034A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71282505P 2005-09-01 2005-09-01

Publications (1)

Publication Number Publication Date
TW200745034A true TW200745034A (en) 2007-12-16

Family

ID=37607561

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095132103A TW200745034A (en) 2005-09-01 2006-08-31 New compounds

Country Status (13)

Country Link
US (1) US20090042856A1 (enExample)
EP (1) EP1919919A1 (enExample)
JP (1) JP5066516B2 (enExample)
KR (1) KR20080049758A (enExample)
CN (1) CN101268079B (enExample)
AU (1) AU2006285599A1 (enExample)
BR (1) BRPI0617100A2 (enExample)
CA (1) CA2620740A1 (enExample)
IL (1) IL189697A0 (enExample)
NO (1) NO20081572L (enExample)
RU (1) RU2008112290A (enExample)
TW (1) TW200745034A (enExample)
WO (1) WO2007026950A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200904421A (en) * 2007-05-03 2009-02-01 Astellas Pharma Inc New compounds
US8188083B2 (en) 2007-06-28 2012-05-29 Abbott Laboratories Triazolopyridazines
US8304413B2 (en) 2008-06-03 2012-11-06 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
JP5790348B2 (ja) * 2010-09-08 2015-10-07 住友化学株式会社 ピリダジノン化合物の製造法およびその製造中間体
EP2763987B1 (en) 2011-10-06 2018-07-18 Bayer CropScience AG Heterocyclylpyri(mi)dinylpyrazole as fungicidals
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
CN104884458B (zh) 2013-04-25 2017-04-12 百济神州有限公司 作为蛋白质激酶抑制剂的稠合杂环化合物
SG11201601844TA (en) 2013-09-13 2016-04-28 Beigene Ltd Anti-pd1 antibodies and their use as therapeutics and diagnostics
RU2692485C2 (ru) 2014-04-02 2019-06-25 Интермьюн, Инк. Противофиброзные пиридиноны
CN110156892B (zh) 2014-07-03 2023-05-16 百济神州有限公司 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
CN106146404B (zh) * 2015-04-15 2020-03-20 江苏恩华药业股份有限公司 哒嗪酮类衍生物及其应用
WO2018007885A1 (en) 2016-07-05 2018-01-11 Beigene, Ltd. COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER
EA201990519A1 (ru) 2016-08-16 2019-08-30 Бейджин, Лтд. КРИСТАЛЛИЧЕСКАЯ ФОРМА (S)-7-(1-АКРИЛОИЛПИПЕРИДИН-4-ИЛ)-2-(4-ФЕНОКСИФЕНИЛ)-4,5,6,7-ТЕТРАГИДРОПИРАЗОЛО[1,5-a]ПИРИМИДИН-3-КАРБОКСАМИДА, ЕЕ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЯ
AU2017313085B2 (en) 2016-08-19 2024-06-20 Beone Medicines I Gmbh Use of a combination comprising a Btk inhibitor for treating cancers
CR20190157A (es) 2016-08-31 2019-08-13 Agios Pharmaceuticals Inc Inhibidores de procesos metabólicos celulares
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
TWI774726B (zh) 2017-01-25 2022-08-21 英屬開曼群島商百濟神州有限公司 (S)-7-(1-(丁-2-炔醯基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氫吡唑并[1,5-a]嘧啶-3-甲醯胺的晶型、及其製備和用途
EP3612522A4 (en) 2017-04-18 2021-07-07 Celgene Quanticel Research, Inc. THERAPEUTIC COMPOUNDS
TWI877099B (zh) 2017-06-26 2025-03-21 英屬開曼群島商百濟神州有限公司 抗ｐｄ－１抗體或其抗原結合片段在製備治療用於患有肝細胞癌（ｈｃｃ）之藥物的用途
US11377449B2 (en) 2017-08-12 2022-07-05 Beigene, Ltd. BTK inhibitors with improved dual selectivity
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CA3078232A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. Use of p38 inhibitors to reduce expression of dux4
US11786529B2 (en) 2017-11-29 2023-10-17 Beigene Switzerland Gmbh Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
EP3981399A4 (en) 2019-06-10 2023-05-31 BeiGene Switzerland GmbH ORAL SOLID TABLET WITH A TYROSINE KINAS INHIBITOR AND METHOD OF MANUFACTURE THEREOF
TW202112368A (zh) 2019-06-13 2021-04-01 荷蘭商法西歐知識產權股份有限公司 用於治療有關dux4表現之疾病的抑制劑組合
US11786531B1 (en) 2022-06-08 2023-10-17 Beigene Switzerland Gmbh Methods of treating B-cell proliferative disorder

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356897A (en) * 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
AR023966A1 (es) * 1999-05-12 2002-09-04 Fujisawa Pharmaceutical Co Una composicion farmaceutica para la prevencion y/o el tratamiento de la enfermedad de parkinson y los sintomas concomitantes de la misma, y el uso de unantagonista dual receptor de adenosina a1 a2a para preparar dicha composicion
US20040152659A1 (en) * 1999-05-12 2004-08-05 Fujisawa Pharmaceutical Co. Ltd. Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist
AUPQ441499A0 (en) * 1999-12-02 2000-01-06 Fujisawa Pharmaceutical Co., Ltd. Novel compound
WO2006038734A1 (en) * 2004-10-08 2006-04-13 Astellas Pharma Inc. Pyridazinone derivatives cytokines inhibitors

Also Published As

Publication number Publication date
BRPI0617100A2 (pt) 2011-07-12
CA2620740A1 (en) 2007-03-08
JP2009507758A (ja) 2009-02-26
AU2006285599A1 (en) 2007-03-08
RU2008112290A (ru) 2009-10-10
IL189697A0 (en) 2008-06-05
CN101268079B (zh) 2011-09-14
CN101268079A (zh) 2008-09-17
EP1919919A1 (en) 2008-05-14
KR20080049758A (ko) 2008-06-04
NO20081572L (no) 2008-03-31
WO2007026950A1 (en) 2007-03-08
US20090042856A1 (en) 2009-02-12
JP5066516B2 (ja) 2012-11-07

Similar Documents

Publication Publication Date Title
TW200745034A (en) New compounds
MX2009010024A (es) Nuevo compuesto de adenina.
TW200730514A (en) Morpholine type cinnamide compound
WO2008108378A3 (en) Bicyclic oxomorpholine derivative
TW200642683A (en) Heterocyclic compound
MY172034A (en) Intermediate for producing bicyclic ?-amino acid derivative
TW200626559A (en) Anilino-pyrimidine analogs
MY142807A (en) Benzimidazole derivative and use thereof.
NO20075312L (no) N-(N-sulfonylaminometyl)cyklopropankarboksamidderivater nyttige ved smertebehandling
TW200606137A (en) Urea derivatives
MD20110063A2 (en) Herbicidal compositions containing benzoylpyrazole compounds
UA105185C2 (uk) Піроли
MX2009003927A (es) Derivado espirocetal de tioglucosa y uso del mismo como un agente terapeutico para la diabetes.
MY140528A (en) Spiroketal derivatives and their use as therapeutic agents for diabetes
WO2008108380A3 (en) Pyrrole compounds
MXPA05008619A (es) Derivados novedosos de 2-piridincarboxamida.
DE60129210D1 (de) Zyklische amid-derivate
WO2009069736A1 (ja) 含窒素化合物
MX2009007482A (es) Agentes antiparasitarios.
UA95972C2 (ru) Аминопиридиновые производные с селективной ингибирующей активностью в отношении авроры а
MY169179A (en) Novel piperidine compound or salt thereof
TW200744659A (en) Preparation for preventing and ameliorating wrinkle
MX2009008756A (es) Compuesto macrociclico.
MY139612A (en) Benzoxazine derivatives as 5-th6 modulators and uses thereof
EP1775289A4 (en) NEW IMIDAZOLIDINE DERIVATIVES